These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 6329584)

  • 1. Simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model.
    Fuseau E; Sheiner LB
    Clin Pharmacol Ther; 1984 Jun; 35(6):733-41. PubMed ID: 6329584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models.
    Unadkat JD; Bartha F; Sheiner LB
    Clin Pharmacol Ther; 1986 Jul; 40(1):86-93. PubMed ID: 3720181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic-pharmacodynamic (PK-PD) modelling in non-steady-state studies and arterio-venous drug concentration differences.
    Gumbleton M; Oie S; Verotta D
    Br J Clin Pharmacol; 1994 Nov; 38(5):389-400. PubMed ID: 7893578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Semiparametric approach to pharmacokinetic-pharmacodynamic data.
    Verotta D; Beal SL; Sheiner LB
    Am J Physiol; 1989 Apr; 256(4 Pt 2):R1005-10. PubMed ID: 2705568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous modeling of pharmacokinetics and pharmacodynamics: an improved algorithm.
    Verotta D; Sheiner LB
    Comput Appl Biosci; 1987 Nov; 3(4):345-9. PubMed ID: 2898970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic modeling in vivo.
    Holford NH; Sheiner LB
    Crit Rev Bioeng; 1981; 5(4):273-322. PubMed ID: 7023829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.
    Meibohm B; Derendorf H
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):401-13. PubMed ID: 9352388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.
    Sheiner LB; Stanski DR; Vozeh S; Miller RD; Ham J
    Clin Pharmacol Ther; 1979 Mar; 25(3):358-71. PubMed ID: 761446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous pharmacokinetic and pharmacodynamic modeling.
    Colburn WA
    J Pharmacokinet Biopharm; 1981 Jun; 9(3):367-88. PubMed ID: 7288596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic modeling of verapamil effects under steady-state and nonsteady-state conditions.
    Schwartz JB; Verotta D; Sheiner LB
    J Pharmacol Exp Ther; 1989 Dec; 251(3):1032-8. PubMed ID: 2600802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Distribution to Human Tissues: Prediction and Examination of the Basic Assumption in In Vivo Pharmacokinetics-Pharmacodynamics (PK/PD) Research.
    Poulin P
    J Pharm Sci; 2015 Jun; 104(6):2110-2118. PubMed ID: 25808270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indirect pharmacodynamic response models do not require any parametric pharmacokinetic model to be fitted to effect-time data.
    Piotrovsky VK
    Methods Find Exp Clin Pharmacol; 1997 Dec; 19(10):723-9. PubMed ID: 9542723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology.
    Gabrielsson J; Green AR
    J Pharmacol Exp Ther; 2009 Dec; 331(3):767-74. PubMed ID: 19779129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development.
    Caruso A; Frances N; Meille C; Greiter-Wilke A; Hillebrecht A; Lavé T
    J Pharmacol Toxicol Methods; 2014; 70(1):73-85. PubMed ID: 24879942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A two-dimensional mathematical model of non-linear dual-sorption of percutaneous drug absorption.
    George K
    Biomed Eng Online; 2005 Jul; 4():40. PubMed ID: 15992411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A paradigm shift in pharmacokinetic-pharmacodynamic (PKPD) modeling: rule of thumb for estimating free drug level in tissue compared with plasma to guide drug design.
    Poulin P
    J Pharm Sci; 2015 Jul; 104(7):2359-68. PubMed ID: 25943586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nociceptive stimulus modality-related difference in pharmacokinetic-pharmacodynamic modeling of morphine in the rat.
    Shang GW; Liu DN; Yan LH; Cui XY; Zhang KP; Qi C; Chen J
    Pharmacol Biochem Behav; 2006 Oct; 85(2):464-73. PubMed ID: 17126387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model.
    Jacqmin P; Snoeck E; van Schaick EA; Gieschke R; Pillai P; Steimer JL; Girard P
    J Pharmacokinet Pharmacodyn; 2007 Feb; 34(1):57-85. PubMed ID: 17051439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of different pharmacodynamic models for PK-PD modeling of verapamil in renovascular hypertension.
    Bertera FM; Mayer MA; Opezzo JA; Taira CA; Höcht C
    J Pharmacol Toxicol Methods; 2008; 57(3):212-9. PubMed ID: 18442930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.
    Louizos C; Yáñez JA; Forrest ML; Davies NM
    J Pharm Pharm Sci; 2014; 17(1):34-91. PubMed ID: 24735761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.